PF-592379 is a drug developed by Pfizer which acts as a potent, selective and orally active agonist for the dopamine D3 receptor, which was under development as a potential medication for the treatment of female sexual dysfunction and male erectile dysfunction but was never marketed. Unlike some other less selective D3 agonists, a research study showed that PF-592379 has little misuse potential in animal studies, and so was selected for further development and potentially human clinical trials. Development has since been discontinued.
PF-592379 is a drug developed by Pfizer which acts as a potent, selective and orally active agonist for the dopamine D3 receptor, which was under development as a potential medication for the treatment of female sexual dysfunction and male erectile dysfunction but was never marketed. Unlike some other less selective D3 agonists, a research study showed that PF-592379 has little misuse potential in animal studies, and so was selected for further development and potentially human clinical trials. Development has since been discontinued.
== See also == List of investigational sexual dysfunction drugs 7-OH-DPAT PD-128,907 PF-219,061
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).